WO2013012049A1 - 心不全抑制剤 - Google Patents
心不全抑制剤 Download PDFInfo
- Publication number
- WO2013012049A1 WO2013012049A1 PCT/JP2012/068382 JP2012068382W WO2013012049A1 WO 2013012049 A1 WO2013012049 A1 WO 2013012049A1 JP 2012068382 W JP2012068382 W JP 2012068382W WO 2013012049 A1 WO2013012049 A1 WO 2013012049A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- luteolin
- derivative
- glucoside
- represented
- inhibitor
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
Definitions
- the present invention relates to a medicament for suppressing cardiac fibrosis, ventricular wall thickening, cardiac hypertrophy, heart failure such as heart failure, and aneurysm.
- Persistent cardiac hypertrophy increases the risk of heart failure, sudden death, etc. Therefore, it is important to suppress cardiac hypertrophy in order to prevent and suppress heart failure.
- This cardiac hypertrophy is classified into a case where it occurs under physiological conditions due to exercise load and a case where it occurs under non-physiological conditions due to pathological stress reaction of the myocardium.
- ROS reactive oxygen
- Cardiac hypertrophy especially cardiac hypertrophy that occurs under non-physiological conditions due to the pathological stress response of the myocardium, is usually characterized by myocardial fibrosis and thickening of the ventricular wall. Sustained excessive stress on the myocardium due to long-term hypertension and abnormal stress on the myocardium after myocardial infarction often cause cardiac hypertrophy. It is known that when the cardiac hypertrophy persists, the heart fails to function as a pump, leading to heart failure.
- Statins, edaravone, ⁇ -blockers, etc. are expected as drugs for such cardiac hypertrophy, but their effectiveness has not been confirmed yet.
- aneurysms are the largest cause of subarachnoid hemorrhage, but the cause of the onset has not yet been clearly clarified. Although hypertension and arteriosclerosis are cited as risk factors for aneurysms, it is unclear whether they are the direct cause. As a means of treating an aneurysm, other than surgery, the progress of the aneurysm is only prevented with an antihypertensive drug.
- the object of the present invention is to provide a medicine and a food for suppressing heart diseases such as cardiac hypertrophy and heart failure and aneurysms.
- luteolin which is a kind of yellow pigment flavonoid contained in edible plants, is angiotensin in rats.
- it is found that it is useful as a heart failure prevention inhibitor and aneurysm inhibitor, significantly suppressing heart fibrosis, ventricular wall thickening, cardiac hypertrophy, and aneurysm without affecting blood pressure.
- the present invention has been completed.
- luteolin-7-O-glucoside has a high oral absorbability and is useful as a medicine or food for oral consumption.
- the present invention provides a heart disease inhibitor selected from cardiac fibrosis, ventricular wall thickening, cardiac hypertrophy and heart failure, comprising luteolin or a derivative thereof as an active ingredient.
- the present invention also provides an aneurysm inhibitor comprising luteolin or a derivative thereof as an active ingredient.
- the present invention also provides use of luteolin or a derivative thereof for producing an inhibitor of heart disease selected from cardiac fibrosis, ventricular wall thickening, cardiac hypertrophy and heart failure.
- the present invention also provides use of luteolin or a derivative thereof for producing an aneurysm inhibitor.
- the present invention also provides luteolin or a derivative thereof for suppressing heart disease selected from cardiac fibrosis, ventricular wall thickening, cardiac hypertrophy and heart failure.
- the present invention also provides luteolin or a derivative thereof for suppressing an aneurysm.
- the present invention also provides a method for suppressing heart disease selected from cardiac fibrosis, ventricular wall thickening, cardiac hypertrophy and heart failure, characterized by administering an effective amount of luteolin or a derivative thereof.
- the present invention also provides a method for suppressing an aneurysm, which comprises administering an effective amount of luteolin or a derivative thereof.
- the present invention provides a composition for oral consumption containing luteolin-7-O-glucoside.
- Luteolin or a derivative thereof is useful as a pharmaceutical or food for preventing and / or suppressing heart failure because it significantly suppresses cardiac fibrosis, ventricular wall thickening and cardiac hypertrophy which are the causative symptoms of heart failure.
- luteolin or a derivative thereof is useful as a medicine or food for preventing and / or suppressing an aneurysm because it significantly suppresses the aneurysm.
- luteolin or a derivative thereof does not affect blood pressure in the angiotensin II continuous infusion model at doses exhibiting the above-described action, indicating that the above-described action is not an effect caused by lowering blood pressure.
- luteolin or a derivative thereof is particularly useful as a preventive agent for cardiac hypertrophy, heart failure, and aneurysm because it is safe and can be taken for a long time.
- action which has on the blood pressure of a luteolin glycoside is shown. It shows the effect of luteolin glycosides on ventricular wall thickening. It shows the effect of luteolin glycosides on heart and ventricular weight. It shows the effect of luteolin glycoside on the generation of active oxygen in the ventricular wall.
- action which acts on the fibrosis of the ventricular wall of a luteolin glycoside is shown.
- action which acts on the expression of the fibrosis marker gene of the ventricular tissue of a luteolin glycoside is shown.
- the effect of luteolin glycosides on cardiac hypertrophy and heart failure marker gene expression in ventricular tissues is shown.
- action which has on the blood pressure and a body weight with respect to the acute aneurysm model of a luteolin glycoside is shown.
- action (appearance) which has on the aneurysm formation of a luteolin glycoside is shown.
- action (diameter of aneurysm) which has on the aneurysm formation of a luteolin glycoside is shown.
- 1 shows the effect of luteolin glycoside on the formation of aneurysms (arterial wall elastic fiber tear inhibiting effect). The plasma concentrations of luteolin and its glycosides are shown.
- an active ingredient of a heart disease inhibitor selected from heart fibrosis, ventricular wall thickening, cardiac hypertrophy and heart failure of the present invention an aneurysm inhibitor (hereinafter sometimes collectively referred to as a heart failure inhibitor) is luteolin or Its derivatives. Luteolin or a derivative thereof has the following formula (1)
- R 1 to R 4 each independently represents a hydrogen atom, an alkyl group, a sulfo group or a sugar residue
- Examples of the alkyl group represented by R 1 to R 4 include an alkyl group having 1 to 4 carbon atoms. Among them, a methyl group, an ethyl group, an n-propyl group, and an isopropyl group are preferable, and a methyl group is more preferable.
- the sulfo group is a group represented by —SO 3 H.
- sugars constituting the sugar residues represented by R 1 to R 4 include monosaccharides such as glucose, galactose, xylose, mannose, and glucuronic acid; disaccharides such as apiosylglucoside, maltose, cellobiose, and gentibiose; and these A mono- or disaccharide acetylated form, malonylated form, etc. are mentioned. Of these sugar residues, residues derived from monosaccharides or disaccharides are more preferred.
- luteolins or their derivatives may be contained in foods such as eggplant, sesame, perilla, asteraceae, seriaceae, cruciferous, gramineous, legumes, rose, honeysuckle, camellia, etc.
- solanaceous plants include plants belonging to the genus Capsicum, and among them, they are contained in large amounts in capsicum, peppers, paprika and the like.
- Sesame plants include sesame plants, which are abundant in sesame.
- Lamiaceae there is a genus of perilla such as egoma and perilla, mint genus such as mint and peppermint, rosmarinus genus such as rosemary, genus Rosaliaus such as thyme, genus genus such as oregano, and genus Akigiri such as sage. Plant.
- the Asteraceae plants include plants belonging to the genus Shungyoku such as Shungyiku, the genus Achinonokeshi such as lettuce, the deer genus such as chamomile, and the genus Dandelion such as dandelion.
- Examples of the plants of the celery family include plants of the genus Dutch honey, such as celery, the genus Dutch genus, such as parsley, the genus Sisido such as Ashitaba, and the carrot genus of carrot sugar.
- Examples of the cruciferous plants include plants of the genus Brassica such as broccoli and cabbage.
- Examples of the grass family plant include sugarcane.
- Examples of leguminous plants include peanuts and high bosses.
- Examples of rose family plants include apple apples, examples of honeysuckle family include honeysuckle, and examples of camellia family include tea tree.
- the extraction part is preferably an edible part of these plants.
- luteolin or its derivatives from these edible plants, for example, hot water, alcohols such as ethanol, esters such as ethyl acetate, ethers such as diethyl ether and dioxane, halogenated hydrocarbons such as chloroform and dichloromethane, It is preferable to use water or an organic solvent such as ketones such as acetone. Of these, extraction with water or ethanol is particularly preferred. The extraction is preferably performed at a temperature of 0 ° C. to the boiling point of the solvent for 1 hour to 72 hours. The extract can be further purified by column chromatography or the like. Moreover, a commercial item may be used for luteolin or its derivative (s).
- luteolin-7-O-glucoside (7-O- ⁇ -D-glucosyl luteolin) can be obtained by acid hydrolysis of luteolin-7-O-apiosyl (1-2) -glucoside (Japanese Patent Laid-Open No. 2008-2008). -20175).
- luteolin or a derivative thereof may be blended, or a plant extract containing luteolin or a derivative thereof may be blended.
- Luteolin or a derivative thereof has excellent cardiac fibrosis suppression effect, ventricular wall thickening suppression without affecting blood pressure in cardiac hypertrophy, heart failure model, and aneurysm model by continuous infusion of angiotensin II, as shown in Examples below.
- luteolin or a derivative thereof is particularly useful as a cardiac hypertrophy inhibitor, heart failure inhibitor, or aneurysm inhibitor.
- the inhibitor includes both of improving symptoms of these diseases and reducing the risk of developing these diseases.
- the heart failure inhibitor of the present invention can be used not only as a pharmaceutical product but also as a quasi-drug, a food for specified health use, a functional food (oral supplement, health food, nutritional supplement, hospital food, medical food, etc.). .
- the medicament of the present invention can be made into various administration forms by blending luteolin, a derivative thereof or a plant extract containing these with a pharmaceutical carrier as necessary, and includes, for example, oral preparations, An injection, a suppository, an ointment, a patch and the like can be mentioned, and an oral preparation is preferable.
- oral preparations include tablets, granules, fine granules, powders, capsules, syrups and the like.
- the pharmaceutical carrier various organic or inorganic carrier substances commonly used as pharmaceutical materials are used. Excipients, binders, disintegrants, lubricants, colorants in solid preparations; solvents, dissolution aids, suspensions in liquid preparations. It is blended as a turbidity agent, tonicity agent, buffering agent, soothing agent and the like. Moreover, formulation additives such as preservatives, antioxidants, colorants, sweeteners, stabilizers and the like can be used as necessary.
- luteolin When preparing a suppository, luteolin, a derivative thereof or a plant extract containing them is added to a pharmaceutical carrier known in the art, for example, polyethylene glycol, lanolin, cocoa butter, fatty acid triglyceride and the like, if necessary, Tween 80.
- a pharmaceutical carrier known in the art, for example, polyethylene glycol, lanolin, cocoa butter, fatty acid triglyceride and the like, if necessary, Tween 80.
- a surfactant such as (registered trademark)
- it can be produced by a conventional method.
- bases, stabilizers, wetting agents, preservatives and the like that are usually used in luteolin, its derivatives or plant extracts containing them are blended as necessary, and mixed and formulated by conventional methods. It becomes.
- the ointment, cream, gel, paste or the like may be applied to a normal support by a conventional method.
- the amount of luteolin or a derivative thereof to be incorporated in the above-mentioned pharmaceutical or functional food is not constant depending on the symptoms of the patient to which this is to be applied, or its dosage form, but generally an oral preparation per dosage unit form Is about 0.05 to 1000 mg, about 0.01 to 500 mg for injections, and about 1 to 1000 mg for suppositories.
- the daily dose of the pharmaceutical having the above dosage form varies depending on the patient's symptoms, body weight, age, sex, etc., and cannot be determined unconditionally.
- the dose is about 5000 mg, preferably 0.1 to 1000 mg, and is preferably administered once a day or divided into about 2 to 3 times a day.
- luteolin-7-O-glucoside is significantly faster and more excellent in oral absorption than luteolin and luteolin-7-O-apiosylglucoside. Therefore, the composition for oral intake containing luteolin-7-O-glucoside is particularly useful as a composition for medicine and food.
- Example 1 Effects of luteolin glycosides (using luteolin-7-O-glucoside) on cardiac fibrosis / hypertrophy in an oxidative stress-enhanced state by continuous infusion of angiotensin II into 8-week-old male SD rats investigated.
- rats were normally bred.
- angiotensin II group angiotensin II continuous infusion pump was implanted subcutaneously into rats and infused continuously for 7 days.
- Luteolin glycoside coadministration group (Ang II + LMG group) was loaded with luteolin glycoside mixed diet (3.6g luteolin monoglycoside (LMG) per 10kg of feed) for 3 weeks and then angiotensin II continuous infusion pump subcutaneously Implanted and infused continuously for 7 days.
- luteolin glycoside mixed diet 3.6g luteolin monoglycoside (LMG) per 10kg of feed
- angiotensin II continuous infusion pump subcutaneously Implanted and infused continuously for 7 days.
- blood pressure was measured, and after evaluating the ventricular wall thickness by echocardiography, the heart was removed and the weight of the heart and ventricle was measured.
- Reactive oxygen was evaluated by staining with hydroethidine, and the degree of fibrosis was evaluated by Masson trichrome staining.
- Gene expression of fibrosis markers and heart failure markers in ventricular tissues was evaluated by real-time PCR.
- the luteolin glycoside did not reduce the blood pressure increased by continuous administration of angiotensin II.
- ventricular wall thickening due to angiotensin II administration (Ang II) was significantly suppressed by administration of luteolin glycoside.
- FIG. 3 the same effect was observed in the evaluation of heart weight / ventricular weight. As a result, it can be seen that luteolin glycosides do not affect blood pressure, effectively act on the heart, and suppress cardiac hypertrophy.
- the luteolin glycoside significantly suppressed the generation of active oxygen in the ventricular wall by angiotensin II. Furthermore, as shown in FIG. 5, the luteolin glycoside markedly suppressed ventricular wall fibrosis by angiotensin II.
- gene expression of TGF- ⁇ 1 (transforming growth factor) and CTGF (connective tissue growth factor) reflecting fibrosis is an internal standard GAPDH expression, and the expression activation by angiotensin II and luteolin distribution are also corrected. Suppression of expression due to the combined use of saccharides was observed, and the results were consistent with the degree of fibrosis (FIG. 5).
- TGF- ⁇ 1 transforming growth factor
- CTGF connective tissue growth factor
- Example 2 A 12-week-old ApoE gene-deficient female mouse (ApoE ⁇ / ⁇ ) (weight approximately 25 g) is continuously infused with angiotensin II (from 16 to 20 weeks) to prepare an acute aneurysm model, and luteolin glycoside (luteolin- The action of 7-O-glucoside was used).
- rats were normally bred (continuous infusion of physiological saline).
- angiotensin II group Ang II tn-rmol group
- angiotensin II continuous infusion pump was implanted subcutaneously into rats and infused continuously for 4 weeks.
- Luteolin glycoside co-administration group (Ang II + luteolin group) was loaded with luteolin glycoside mixed diet (containing 0.055% luteolin-7-O-glucoside per bait) for 3 weeks and then subcutaneously angiotensin II continuous infusion pump Were implanted for 4 weeks.
- the luteolin glycoside administration group clearly suppressed the formation of an aneurysm.
- the diameter of the aneurysm was small.
- the luteolin glycoside administration group suppressed arterial wall elastic fiber rupture.
- Example 3 Luteolin (51 mg / kg, PO), luteolin-7-O-glucoside (93 mg / kg, PO) and luteolin-7-O-apiosylglucoside (175 mg / kg, PO) were administered to rats (8 weeks old, male SD system). Rat) was orally administered, blood was collected from the tail vein immediately before administration, 0.5 hours, 1 hour, 2 hours and 8 hours later, and the concentration of luteolin in plasma was measured. The dose of each luteolin and its glycoside was the same as the amount of luteolin that is an aglycone. The result is shown in FIG. As is clear from the results in FIG. 12, luteolin-7-O-glucoside showed significantly higher oral absorbability than luteolin and luteolin-7-O-apiosyl glucoside.
Abstract
Description
さらにルテオリン又はその誘導体の中でも、特にルテオリン-7-O-グルコシドが高い経口吸収性を有し、経口摂取用の医薬や食品として有用であることをも見出した。
また、本発明は、ルテオリン又はその誘導体を有効成分とする動脈瘤抑制剤を提供するものである。
また、本発明は、心臓線維化、心室壁肥厚、心肥大及び心不全から選ばれる心疾患の抑制剤製造のための、ルテオリン又はその誘導体の使用を提供するものである。
また、本発明は、動脈瘤抑制剤製造のための、ルテオリン又はその誘導体の使用を提供するものである。
また、本発明は、心臓線維化、心室壁肥厚、心肥大及び心不全から選ばれる心疾患を抑制するための、ルテオリン又はその誘導体を提供するものである。
また、本発明は、動脈瘤抑制のための、ルテオリン又はその誘導体を提供するものである。
また、本発明は、ルテオリン又はその誘導体の有効量を投与することを特徴とする心臓線維化、心室壁肥厚、心肥大及び心不全から選ばれる心疾患の抑制方法を提供するものである。
また、本発明は、ルテオリン又はその誘導体の有効量を投与することを特徴とする動脈瘤の抑制方法を提供するものである。
さらに、本発明は、ルテオリン-7-O-グルコシドを含有する経口摂取用組成物を提供するものである。
また、ルテオリン-7-O-グルコシド(7-O-β-D-グルコシルルテオリン)は、ルテオリン-7-O-アピオシル(1-2)-グルコシドの酸加水分解により得ることができる(特開2008-201795号)。
ここで抑制剤とは、これらの疾患の症状を改善すること、及びこれらの疾患の発症リスクを低下させることの両方を含む。
また、前記投与形態を有する医薬の1日あたりの投与量は、患者の症状、体重、年齢、性別等によって異なり一概には決定できないが、通常成人(体重60kg)1日あたり約0.05~5000mg程度であり、0.1~1000mgが好ましく、これを1日1回又は2~3回程度に分けて投与するのが好ましい。
8週令の雄性SD系ラットにアンジオテンシンIIを持続注入して、酸化ストレス亢進状態におかれた心臓線維化・心肥大に対するルテオリン配糖体(ルテオリン-7-O-グルコシドを使用)の作用を検討した。コントロール群は、ラットを普通飼育した。アンジオテンシンII群(Ang II群)は、ラットの皮下にアンジオテンシンII持続注入ポンプを植え込み、7日間持続注入した。ルテオリン配糖体同時投与群(Ang II+LMG群)は、ルテオリン配糖体配合餌(餌10kgにつき3.6gルテオリンモノグリコシド(LMG)を配合)を3週間負荷後、皮下にアンジオテンシンII持続注入ポンプを植え込み、7日間持続注入した。
7日目に血圧を測定し、心エコー検査で心室壁肥厚度を評価後、心臓を摘出し、心臓および心室の重量を測定した。活性酸素はハイドロエチジン染色することにより、また線維化の程度はマッソントリクローム染色により評価した。心室組織における線維化マーカー、心不全マーカーの遺伝子発現をリアルタイムPCR法で評価した。
12週令のApoE遺伝子欠損雌性マウス(ApoE-/-)(体重約25g)にアンジオテンシンIIを持続注入(16週から20週)して急性動脈瘤モデルを作製し、ルテオリン配糖体(ルテオリン-7-O-グルコシドを使用)の作用を検討した。コントロール群(n=5)は、ラットを普通飼育した(生理食塩水を持続注入)。アンジオテンシンII群(Ang II tn-rmol群)は、ラットの皮下にアンジオテンシンII持続注入ポンプを植え込み、4週間持続注入した。ルテオリン配糖体同時投与群(Ang II+luteolin群)は、ルテオリン配糖体配合餌(餌につき0.055%ルテオリン-7-O-グルコシドを配合)を3週間負荷後、皮下にアンジオテンシンII持続注入ポンプを植え込み、4週間持続注入した。
ルテオリン(51mg/kg,PO)、ルテオリン-7-O-グルコシド(93mg/kg,PO)及びルテオリン-7-O-アピオシルグルコシド(175mg/kg,PO)をラット(8週令、雄性SD系ラット)に経口投与し、投与直前、0.5時間、1時間、2時間及び8時間後に尾静脈から採血し、血漿中のルテオリン濃度を測定した。なお、各ルテオリン及びその配糖体の投与量は、アグリコンであるルテオリン量として同一とした。
その結果を図12に示す。図12の結果から明らかなように、ルテオリン-7-O-グルコシドは、ルテオリン及びルテオリン-7-O-アピオシルグルコシドに比べて顕著に高い経口吸収性を示した。
Claims (26)
- ルテオリン又はその誘導体を有効成分とする心不全、心臓線維化、心室壁肥厚及び心肥大から選ばれる心疾患の抑制剤。
- ルテオリン又はその誘導体が、ルテオリン又はルテオリン-7-O-グルコシドである請求項1又は2記載の心疾患の抑制剤。
- ルテオリン又はその誘導体を有効成分とする動脈瘤抑制剤。
- ルテオリン又はその誘導体が、ルテオリン又はルテオリン-7-O-グルコシドである請求項4又は5記載の動脈瘤抑制剤。
- 心不全、心臓線維化、心室壁肥厚及び心肥大から選ばれる心疾患の抑制剤製造のための、ルテオリン又はその誘導体の使用。
- ルテオリン又はその誘導体が、ルテオリン又はルテオリン-7-O-グルコシドである請求項7又は8記載の使用。
- 動脈瘤抑制剤製造のための、ルテオリン又はその誘導体の使用。
- ルテオリン又はその誘導体が、ルテオリン又はルテオリン-7-O-グルコシドである請求項10又は11記載の使用。
- 心不全、心臓線維化、心室壁肥厚及び心肥大から選ばれる心疾患を抑制するための、ルテオリン又はその誘導体。
- ルテオリン又はその誘導体が、ルテオリン又はルテオリン-7-O-グルコシドである請求項13又は14記載の化合物。
- 動脈瘤を抑制するための、ルテオリン又はその誘導体。
- ルテオリン又はその誘導体が、ルテオリン又はルテオリン-7-O-グルコシドである請求項16又は17記載の化合物。
- ルテオリン又はその誘導体の有効量を投与することを特徴とする、心不全、心臓線維化、心室壁肥厚及び心肥大から選ばれる心疾患を抑制する方法。
- ルテオリン又はその誘導体が、ルテオリン又はルテオリン-7-O-グルコシドである請求項19又は20記載の方法。
- ルテオリン又はその誘導体の有効量を投与することを特徴とする、動脈瘤の抑制方法。
- ルテオリン又はその誘導体が、ルテオリン又はルテオリン-7-O-グルコシドである請求項22又は23記載の方法。
- ルテオリン-7-O-グルコシドを含有する経口摂取用組成物。
- 医薬又は食品用組成物である請求項25記載の組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2841724A CA2841724C (en) | 2011-07-20 | 2012-07-19 | Use of luteolin and derivatives thereof in the prevention and treatment of heart failure |
US14/233,581 US9326990B2 (en) | 2011-07-20 | 2012-07-19 | Heart failure suppressing agent |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-158920 | 2011-07-20 | ||
JP2011158920 | 2011-07-20 | ||
JP2011193508 | 2011-09-06 | ||
JP2011-193508 | 2011-09-06 | ||
JP2012116387A JP2013067605A (ja) | 2011-07-20 | 2012-05-22 | 心不全抑制剤 |
JP2012-116387 | 2012-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013012049A1 true WO2013012049A1 (ja) | 2013-01-24 |
Family
ID=47558224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/068382 WO2013012049A1 (ja) | 2011-07-20 | 2012-07-19 | 心不全抑制剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9326990B2 (ja) |
JP (1) | JP2013067605A (ja) |
CA (1) | CA2841724C (ja) |
WO (1) | WO2013012049A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014180234A (ja) * | 2013-03-19 | 2014-09-29 | Toa Eiyo Ltd | 急性心不全モデル、これを用いた急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016170704A1 (ja) * | 2015-04-23 | 2016-10-27 | 株式会社日本ハイポックス | 慢性呼吸器疾患治療剤及び心臓の線維化抑制組成物 |
CN105769896B (zh) * | 2016-03-01 | 2019-04-30 | 上海中医药大学附属岳阳中西医结合医院 | 木犀草素-7-二葡萄糖醛酸苷在制备抗心肌损伤或纤维化的药物中的应用 |
JP2019019090A (ja) * | 2017-07-19 | 2019-02-07 | 共栄化学工業株式会社 | TGF−β合成抑制剤 |
JP2019089754A (ja) * | 2017-11-14 | 2019-06-13 | 株式会社明治 | 心疾患治療用組成物 |
US10987394B2 (en) | 2017-12-22 | 2021-04-27 | Industrial Technology Research Institute | Method for preparing an extract of Chrysanthemum morifolium with an effect of treating skin diseases, extract of Chrysanthemum morifolium with an effect of treating skin diseases and pharmaceutical composition containing the extract |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09143070A (ja) * | 1995-09-22 | 1997-06-03 | Nippon Flour Mills Co Ltd | リパーゼ阻害剤及び血中トリグリセライド低下剤 |
JPH1095732A (ja) * | 1996-09-19 | 1998-04-14 | Nippon Flour Mills Co Ltd | グリセロリン酸脱水素酵素阻害剤 |
-
2012
- 2012-05-22 JP JP2012116387A patent/JP2013067605A/ja active Pending
- 2012-07-19 US US14/233,581 patent/US9326990B2/en active Active
- 2012-07-19 CA CA2841724A patent/CA2841724C/en active Active
- 2012-07-19 WO PCT/JP2012/068382 patent/WO2013012049A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09143070A (ja) * | 1995-09-22 | 1997-06-03 | Nippon Flour Mills Co Ltd | リパーゼ阻害剤及び血中トリグリセライド低下剤 |
JPH1095732A (ja) * | 1996-09-19 | 1998-04-14 | Nippon Flour Mills Co Ltd | グリセロリン酸脱水素酵素阻害剤 |
Non-Patent Citations (9)
Title |
---|
A F E RUMP, ET AL.: "Functional and antiischemic effects of luteolin-7-glucoside in isolated rabbit hearts", GEN. PHARMACOL., vol. 25, no. 6, October 1994 (1994-10-01), pages 1137 - 1142 * |
GLORIA GUTIERREZ-VENEGAS, ET AL.: "The flavonoids luteolin and quercetagetin inhibit lipoteichoic acid actions on H9c2 cardiomyocytes", INT. IMMUNOPHARMACOL., vol. 10, no. 9, September 2010 (2010-09-01), pages 1003 - 1009 * |
HIDEO A. BABA, ET AL.: "Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism", CARDIOVASCUL. RES., vol. 59, 2003, pages 390 - 399 * |
JUNG-SUK CHOI, ET AL.: "Flavones Mitigate Tumor Necrosis Factor-g-Induced Adhesion Molecule Upregulation in Cultured Human Endothelial Cells: Role of Nuclear Factor-kB", J. NUTR., vol. 134, 2004, pages 1013 - 1019 * |
MING-JIUAN WU, ET AL.: "Antioxidant Activity of Glossogyne tenuifolia", J. AGRIC. FOOD CHEM., vol. 53, no. 16, 2005, pages 6305 - 6312 * |
MOLECULAR CARDIOVASCULAR MEDICINE, vol. 7, no. 6, 2006, pages 574 - 579 * |
MOLECULAR CARDIOVASCULAR MEDICINE, vol. 8, no. 1, 2007, pages 22 - 26 * |
NUTR. CARE, vol. 2, no. 6, 2009, pages 612 - 616 * |
SYED HAQ, ET AL.: "Differential Activation of Signal Transduction Pathways in Human Hearts With Hypertrophy Versus Advanced Heart Failure", CIRCULATION, vol. 103, 6 February 2001 (2001-02-06), pages 670 - 677 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014180234A (ja) * | 2013-03-19 | 2014-09-29 | Toa Eiyo Ltd | 急性心不全モデル、これを用いた急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法 |
Also Published As
Publication number | Publication date |
---|---|
US20140194372A1 (en) | 2014-07-10 |
JP2013067605A (ja) | 2013-04-18 |
CA2841724C (en) | 2018-05-29 |
CA2841724A1 (en) | 2013-01-24 |
US9326990B2 (en) | 2016-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013012049A1 (ja) | 心不全抑制剤 | |
KR102292989B1 (ko) | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 | |
US20110038959A1 (en) | Plant-origin drug for preventing or improving hyperuricemia | |
US20200254105A1 (en) | Drug composition for parenteral administration | |
CN109771431A (zh) | 和厚朴酚衍生物的新用途 | |
CN104640573A (zh) | 萝卜硫烷的分离和纯化 | |
EP3064209A1 (en) | Composition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside f2 | |
JP6377713B2 (ja) | 薬剤 | |
US20130116321A1 (en) | Composition containing serine as an active ingredient for the prevention and treatment of fatty liver diseases, and the use thereof | |
KR20130135226A (ko) | 레티놀, 그의 전구물질 또는 반응 생성물 및 1종 이상의 카모밀라 식물로부터의 식물 추출물을 포함하는, 암의 치료를 위한 조성물 | |
JP2004043373A (ja) | リパーゼ阻害剤 | |
JP6288625B2 (ja) | 心不全抑制剤 | |
KR20210047594A (ko) | 하이드란제놀 또는 필로둘신을 유효성분으로 하는 피부장벽 강화 및 아토피 피부염 개선용 조성물 | |
KR20070044198A (ko) | 푸마르산 및 푸마르산 유도체를 유효성분으로 함유하는대사증후군 치료제 | |
KR101708368B1 (ko) | 당대사 개선용 조성물 및 그 조성물을 함유하는 의약 제제 | |
KR101089716B1 (ko) | 플라보노이드계 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 고지혈증, 고콜레스테롤혈증 또는 이들의 합병증의 예방 및 치료용 조성물 | |
KR20200080892A (ko) | 피페로날을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생, 근감소증 억제효과를 갖는 조성물 | |
WO2014035214A1 (ko) | 족제비싸리 추출물을 포함하는 조성물 | |
WO2021201264A1 (ja) | 変形性関節症の治療、予防又は緩和のための非経口投与用医薬組成物 | |
KR102069125B1 (ko) | 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물 | |
KR102099510B1 (ko) | 푸니칼라진을 포함하는 par2 활성 억제용 조성물 | |
JP4825957B2 (ja) | 抗腫瘍剤 | |
WO2014017741A1 (ko) | 프루네틴을 유효성분으로 함유하는 비만 또는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
KR20080093783A (ko) | 흰민들레의 분획물, 제조방법 및 이의 용도 | |
KR20230069853A (ko) | 근육 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12814743 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2841724 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14233581 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12814743 Country of ref document: EP Kind code of ref document: A1 |